Today, FAH submitted comments to the Federal Trade Commission (FTC) and Department of Justice, Antitrust Division (together, the Agencies) on the Requests for Public Comment Regarding Reducing Anti-Competitive Regulatory Barriers. FAH comments highlighted various federal and […]
Read More… from FAH Urges DOJ/FTC Action on Anti-Competitive Laws and Regulations
FAH President and CEO Chip Kahn released the following statement regarding President Trump’s Executive Order (EO) titled “Lowering Drug Prices By Once Again Putting Americans First“: “President Trump’s EO to lower drug costs for Americans […]
FAH President and CEO Chip Kahn released the following statement after CMS released the Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 Final Rule: “CMS’s decision to brush aside the Medicare statute […]
Read More… from “Dangerous Precedent” – FAH Leader Reacts to CMS 340B Remedy with Recoupment
